# China NMPA Drug Inspection - Heilongjiang Tongyu Pharmaceutical Packaging Co., Ltd. - Pharmaceutical aluminum foil

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/heilongjiang-tongyu-pharmaceutical-packaging-co-ltd/769f3e67-c69e-403d-b103-fd28961d17b0/
Source feed: China

> China NMPA drug inspection for Heilongjiang Tongyu Pharmaceutical Packaging Co., Ltd. published June 29, 2017. Drug: Pharmaceutical aluminum foil. The National Medical Products Administration (NMPA), formerly the State Food and Drug Administration (SFDA), announced o

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: State Administration for Market Regulation Announcement No. 99 of 2017 Regarding 3 Batches of Substandard Drug Packaging Materials
- Company Name: Heilongjiang Tongyu Pharmaceutical Packaging Co., Ltd.
- Publication Date: 2017-06-29
- Drug Name: Pharmaceutical aluminum foil
- Inspection Finding: The non-compliant items included identification and dissolution tests.
- Action Taken: Control measures such as sealing and seizing have been taken, requiring enterprises to suspend sales and use, recall products and rectify the situation, and an investigation has been launched into the illegal production and sale of substandard products.
- Summary: The National Medical Products Administration (NMPA), formerly the State Food and Drug Administration (SFDA), announced on June 29, 2017, findings from quality control tests on drug packaging materials. Three companies were identified for producing substandard products: Anhui Huafeng Pharmaceutical Rubber Co., Ltd., Kunming Fusheng Gaopin Plastics Co., Ltd., and Heilongjiang Tongyu Pharmaceutical Packaging Co., Ltd.The violations pertained to specific batches of their products: Anhui Huafeng's injection stoppers (batch G1606010B), Kunming Fusheng's oral medicine bottles (batch 201605001), and Heilongjiang Tongyu's pharmaceutical aluminum foil (batch YB160406). Issues primarily involved failures in "identification and dissolution tests," indicating non-compliance with established quality standards for drug packaging.Under the regulatory framework of the *Drug Administration Law of the People's Republic of China*, immediate actions were mandated. Provincial food and drug administrations implemented control measures, including sealing and seizing the affected products. The implicated companies were required to suspend sales, recall the substandard batches, and implement corrective actions. Furthermore, provincial authorities were instructed to investigate the companies for illegal activities, publicly disclose investigation outcomes within three months, and report findings to the NMPA. This enforcement action underscores the NMPA's commitment to ensuring the quality and safety of pharmaceutical products in China.

Company: https://www.globalkeysolutions.net/companies/heilongjiang-tongyu-pharmaceutical-packaging-co-ltd/9708cd88-6d07-4578-9abf-1a2dc0ef4f26/